Bumetanide NDC 51672-4223

NDC codes

FDA NDC Directory

Product NDC (as listed)51672-4223Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51672-4223Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51672-4223-1	51672422301	100 TABLET in 1 BOTTLE (51672-4223-1)Marketed from Jul 24, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Bumetanide
Generic name (nonproprietary): bumetanide
Active ingredients: Bumetanide — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213458
Marketing start: Jul 24, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Increased Diuresis at Loop of Henle (Physiologic effect)
Identifiers: Product ID 51672-4223_4db68936-9d9c-1821-e063-6394a90a7f1bSPL ID 4db68936-9d9c-1821-e063-6394a90a7f1bSPL set ID 5c753aae-77b7-4add-8453-385a8f62d7dbRxCUI 197417, 197418, 197419UNII 0Y2S3XUQ5HUPC 0351672422417
Pharmacologic class: Loop Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451672422301 followed by a unit qualifier and the quantity

Package 51672-4223-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 23, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Bumetanide tablets, USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213458

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213458
Product	Strength	Form · route	Labeler	Product NDC
Bumetanide	Bumetanide 2 mg/1	TabletOral	Sun Pharmaceutical Industries, Inc.	51672-4225
Bumetanide	Bumetanide 1 mg/1	TabletOral	Sun Pharmaceutical Industries, Inc.	51672-4224